Apellis Pharmaceuticals, Inc. — Director's Dealing 2020

Jun 10, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2020-06-01

Reporting Person: Lewis Karen (Chief People Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$34.11	2030-05-03	Common Stock (116000)		Direct

Footnotes

F1: This stock option was granted on 5/4/2020 and has a four year vesting period. 25% vest one year from grant date. The remaining 75% vest monthly over the last three years of the four year vesting period.